5
、 監測動物用藥品使用情形
ٜ͟ᒍ̹eጤִ̹݁ၾᇆ
ݟ
ɛ
ࡰ
ࠌ
9,357
ϣळ
ى
ఙ
פ
᜕ळА૰e
ອЂe͛Ԫʿອஐഃᅵۜ
4
ຬ
668
d
္ᗳᖹ
ي
Դ͜ઋҖdΥࣸଟ
މ
99.79
Ĉf̤̋੶
פ
᜕༼
ج
Դ͜ɔۨա
९dᇆ
ݟ
̹ਯळອପۜɔۨա९ಞ
व
1
ຬ
2,329
dΥࣸଟ
މ
99.98
Ĉf
6
、 畜禽細菌抗藥性監測
OIE
ί
2013
ϋ০࿁ഽҤᖹᑊʕ
ڌ
ͪjҤ͛९݊ၪܵਗ
ي
ੰၾ၅лʘ
ࠠ
ࠅ
ʈՈiҤ͛९࿁ΌଢτΌۜՈϞ
্ᘠiഽҤᖹ̙ீཀɛeਗ
ي
eᐑ
ྤʝෂᅧdၾʝෂᅧfฆ͛
ي
ҤᖹӚϞήਹ
א
ɛÿਗ
ي
ምም
ܝ
ʘਪᕚfઓอᖹ೯
ܓ
ჃʔʿҤᖹ
೯࢝d݂Ҥ͛९Ҥᖹᙄᕚʊစᜊ
މ
ࠠ
ɽʘʮሊ͛ᙄᕚd
۾
উഹषɛᚐe
ϓ
ڗ
eʮሊ͛eุ༵eʿ
τΌf˰
ޢ
ሊ͛ଡ଼ᔌ
WHO
ʿ
OIE
ᙆᙂՑவ
ࡈ
ᘌഠሙᕚd
ࡇ
ᙄੰ
ɓ
One Health
dխᝫΝ
ࠦ࿁ฆ͛
ي
Ҥᖹਪᕚf
c
OIE
ܔ
ᙄᏐϞΌҁᖕᔼਕ
ӻʿ੶ʷͭ
ج
ӻԸછՓʿ༆Ӕᗫਪ
ᕚfϾΌҁᖕᔼਕӻܼ̍j
͟ਖ਼ุᖕᔼɛࡰකͭஈ˙၏˙ഗʚᖹ
ي
e္ਗ
ي
Ҥ͛९Դ͜ඎʿฆ͛
ي
Ҥ
ᖹi੶ʷͭ
ج
ӻ
ۆ
ܼ̍j
ܔ
ִͭ݁
္ຖӻeࠢՓҤ͛९னርe͛ପၾආ
ɹiʮ္̺ᅰኽഃણ݄f
˰
ޢ
ආޫ౷ཁආБഽҤᖹ
္dҢ͵ʊԱኽ
OIE
ܔ
ᙄੂБᗫ
ৣࢁણ݄ʿ္
ࠇ
f
މ
ᐝ༆ਗ
ي
͜Ҥ
ഽኒ၍ଣઋҖdҢ։ৄৌྠ
ج
ɛ༵
ุ߅ҦӺ৫ආБळອഽҤᖹ္
ʈЪd༈္̻ၽਞϽʗҤᖹ
္ӻ୕dІlzळອਜ਼ఙ
א
Ђۜ
̹ఙϗණਗ
ي
ԁ
ژ
ᐰ
ک
ᏨdԱ
OIE
̺ʘ͛ਗ
جي
ՊආБ໑༸ܸᅺഽɽ໑
ഽձ໑ଢഽʱᕎfʱᕎʘฆ͛
ي
Ա
The Clinical and Laboratory Standards
Institute
CLSI
ყᅺ˙
ج
ආБᖹ
ي
ઽช༊᜕f
Ҥᖹ္ٙᖹ
ي
ܼ̍j
Amoxicillin
e
Ce f t i o f u r
e
Ch l o r amph en i c o l
e
E n r o f l o x a c i n
e
K a n a m y c i n
e
L i ncomy c i n
e
Ox y t e t r ac y c l i ne
e
Tylosin
e
Vancomycin
ഃ
9
၇f Ա ኽ
WHO
ၾ
OIE
ʮ̺ɛᗳᔼኪၾᖕᔼኪ
ࠠ
ࠅ
ҤഽኒఊdԱࠠ
ࠅ
ʱ
މ
ܓ
ࠠ
ࠅ
e৷
ܓ
ࠠ
ࠅ
eࠠ
ࠅ
ɧॴfͦ
ۃ
္ ᖹ
ي
Amoxicillin
e
Ceftiofur
e
Enrofloxacin
e
Kanamycin
e
Tylosin
ʿ
Vancomyc i n
᙮
ܓ
ࠠ
ࠅ
d
Chloramphenicol
e
Lincomycin
ʿ
Oxytetracycline
ܓ৷᙮
ࠠ
ࠅ
f
͟ळອ໑༸ฆ͛
ي
Ҥᖹ္ഐ
؈
ʱؓd
ܓ
ࠠ
ࠅ
Ҥഽኒ
Ceftiofur
e
Enrofloxacin
e
Kanamycin
ίɽ໑ഽ
ʘҤᖹяତɨࠥᒈැd
Amoxicillin
я ତ ܵ ̻ ᒈ ැi ৷
ܓ
ࠠ
ࠅ
Ҥ ഽ ኒ
Chloramphenicol
ձ
Oxytetracycline
ۆ
яତ̻ܵᒈැf໑ଢഽʘҤᖹ္ഐ
؈
Ҥഽኒѩяତ̻ܵ
א
ɨࠥᒈැd
˲ ዝ ϋ Ը
Amoxicillin
e
Enrofloxacin
ձ
Vancomycin
ޫ ၪ ܵ Э Ҥ ᖹ ˢ
ଟf̤तй
࠽
ء
จٙ݊Ҥຬ̚
९ ໑ ଢ ഽ
vancomycin
Ñ
resistant
Enterococcus, VRE
ၾ Ҥ ຬ ̚ ९
܇ ໑ ଢ ഽ
vancomycin
Ñ
resistant
Enterococcus faecium
ʘҤᖹˢ
ଟdѩЭ
א
ೌᏨ̈f
12
ਗಔ
ي
ԣ
ޥ
Ꮸ
ޥ
҅
106
ϋజ